Proton pump inhibitor use and the risk of chronic kidney disease

JAMA Internal Medicine

Volumn 176, Issue 2, 2016, Pages 238-246

  Lazarus, Benjamin ^a   Chen, Yuan ^b   Wilson, Francis P ^c   Sang, Yingying ^d   Chang, Alex R ^e   Coresh, Josef ^a   Grams, Morgan E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DEATH; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SELF REPORT; SENSITIVITY ANALYSIS; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; INCIDENCE; MULTICENTER STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; UNITED STATES;

ADULT; AGED; COHORT STUDIES; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; UNITED STATES;

EID: 84957998974     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.7193     Document Type: Article

References (32)

1. United States Renal Data System. 2014 USRDS Annual Data Report: An overview of the epidemiology of kidney disease in the United States. http://www.usrds.org/2014/view/Default .aspx. Published 2014. Accessed April 3, 2015.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.
4. Grams ME, Juraschek SP, Selvin E, et al. Trends in the prevalence of reduced GFR in the United States: A comparison of creatinine-And cystatin C-based estimates. Am J Kidney Dis. 2013;62(2): 253-260.
5. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
6. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2-3.
7. Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. PharmWorld Sci. 2006;28(4):189-193.
8. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6(4): 443-451.
9. Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45(4): 421-427.
10. De Bruyne P, Christiaens T, Vander Stichele R, VanWinckel M. Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: Analysis of the national database, [1997-2009]. J Pediatr Gastroenterol Nutr. 2014;58 (2):220-225.
11. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953.
12. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-Acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-Analysis. PLoS One. 2015;10(6):e0128004. doi:10.1371/journal.pone.0128004.
13. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33-38.
14. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4): 837-844.
15. Sierra F, Suarez M, ReyM, VelaMF. Systematic review: proton pump inhibitor-Associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007; 26(4):545-553.
16. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open. 2015;3(2):E166-E171. doi:10.9778/cmajo.20140074.
17. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: A nested case-control study. BMC Nephrol. 2013;14:150.
18. Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21(11):1155-1172.
19. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: A systematic review and meta-Analysis. Kidney Int. 2012;81(5):442-448.
20. Hrmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol. 2007;64(6):819-823.
21. Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: A systematic review and meta-Analysis. PLoS One. 2014;9(11):e112558. doi:10.1371/journal.pone.0112558.
22. Tin A, Grams ME, Maruthur NM, et al. Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int. 2015;87 (4):820-827.
23. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol. 1989;129(4):687-702.
24. Grams ME, Rebholz CM, McMahon B, et al. Identification of incident CKD stage 3 in research studies. Am J Kidney Dis. 2014;64(2):214-221.
25. Rebholz CM, Coresh J, Ballew SH, et al. Kidney failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) study: comparing ascertainment of treated and untreated kidney failure in a cohort study. Am J Kidney Dis. 2015;66 (2):231-239.
26. Grams ME, Waikar SS, MacMahon B, Whelton S, Ballew SH, Coresh J. Performance and limitations of administrative data in the identification of AKI. Clin J AmSoc Nephrol. 2014;9(4):682-689.
27. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
28. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11 (7):437-441.
29. IMS Institute for Healthcare Informatics. Medicine use and shifting costs of healthcare: A review of the use of medicines in the United States in 2013. http://www.imshealth.com/cds /imshealth/Global/Content/Corporate/IMS %20Health%20Institute/Reports/Secure/IIHI-US-Use-of-Meds-for-2013.pdf. Published April 2014. Accessed June 19, 2015.
30. Bjrnsson E, Abrahamsson H, Simrn M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: A double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945-954.
31. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66-68.
32. Danaei G, TavakkoliM, Hernn MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-Analysis of statins. Am J Epidemiol. 2012;175 (4):250-262.